DARPP-32: An Integrator of Neurotransmission

Annual Review of Pharmacology and Toxicology

Volumn 44, Issue , 2004, Pages 269-296

  Svenningsson, Per ^a   Nishi, Akinori ^a,b   Fisone, Gilberto ^a,c   Girault, Jean Antoine ^d   Nairn, Angus C ^a,e   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

^d INSERM   (France)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Basal ganglia; Dopamine; Glutamate; Protein phosphorylation; Signal transduction; Striatum

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; DOPAMINE; ILLICIT DRUG; NEUROLEPTIC AGENT; NEUROPEPTIDE; NEUROTRANSMITTER; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE 1; SERINE; STEROID HORMONE; THREONINE;

BRAIN REGION; CORPUS STRIATUM; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; HUMANS; NERVE TISSUE PROTEINS; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEINS; PHOSPHORYLATION; SYNAPTIC TRANSMISSION;

EID: 1342323630     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.44.101802.121415     Document Type: Review

References (131)

1. Walaas SI, Aswad DW, Greengard P. 1983. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 301:69-71
2. Greengard P. 2001. The neurobiology of slow synaptic transmission. Science 294:1024-30
3. Williams KR, Hemmings HC Jr, LoPresti MB, Konigsberg WH, Greengard P. 1986. DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor-1. J. Biol. Chem. 261:1890-903
4. Gustafson EL, Girault JA, Hemmings HC Jr, Nairn AC, Greengard P. 1991. Immunocytochemical localization of phosphatase inhibitor-1 in rat brain. J. Comp. Neurol. 310:170-88
5. Hemmings HC Jr, Greengard P, Tung HY, Cohen P. 1984. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310:503-5
6. Ouimet CC, Langley-Gullion KC, Greengard P. 1998. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res. 808:8-12
7. Ouimet CC, Miller PE, Hemmings HC Jr, Walaas SI, Greengard P. 1984. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J. Neurosci. 4:111-24
8. da Cruz e Silva EF, Fox CA, Ouimet CC, Gustafson E, Watson SJ, Greengard P. 1995. Differential expression of protein phosphatase 1 isoforms in mammalian brain. J. Neurosci. 15:3375-89
9. Hemmings HC Jr, Williams KR, Konigsberg WH, Greengard P. 1984. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated neuronal phosphoprotein. I. Amino acid sequence around the phosphorylated threonine. J. Biol. Chem. 259:14486-90
10. Hemmings HC Jr, Nairn AC, Elliott JI, Greengard P. 1990. Synthetic peptide analogs of DARPP-32 (Mr 32,000 dopamine- and cAMP-regulated phosphoprotein), an inhibitor of protein phosphatase-1. Phosphorylation, dephosphorylation, and inhibitory activity. J. Biol. Chem. 265:20369-76
11. Desdouits F, Cheetham JJ, Huang HB, Kwon YG, da Cruz e Silva EF, et al. 1995. Mechanism of inhibition of protein phosphatase 1 by DARPP-32: studies with recombinant DARPP-32 and synthetic peptides. Biochem. Biophys. Res. Commun. 206:652-58
12. Kwon YG, Huang HB, Desdouits F, Girault JA, Greengard P, Nairn AC. 1997. Characterization of the interaction between DARPP-32 and protein phosphatase 1 (PP-1): DARPP-32 peptides antagonize the interaction of PP-1 with binding proteins. Proc. Natl. Acad. Sci. USA 94:3536-41
13. Huang HB, Horiuchi A, Watanabe T, Shih SR, Tsay HJ, et al. 1999. Characterization of the inhibition of protein phosphatase-1 by DARPP-32 and inhibitor-2. J. Biol. Chem. 274:7870-78
14. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D. 1997. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO J. 16:1876-87
15. Hsieh-Wilson LC, Allen PB, Watanabe T, Nairn AC, Greengard P. 1999. Characterization of the neuronal targeting protein spinophilin and its interactions with protein phosphatase-1. Biochemistry 38:4365-73
16. Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, et al. 1999. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat. Neurosci. 2:13-17
17. Morishita W, Connor JH, Xia H, Quinlan EM, Shenolikar S, Malenka RC. 2001. Regulation of synaptic strength by protein phosphatase 1. Neuron 32:1133-48
18. Greengard P, Allen PB, Nairn AC. 1999. Beyond the dopamine receptor: the DARPP 32/protein phosphatase-1 cascade. Neuron 23:435-47
19. Girault JA, Hemmings HC Jr, Williams KR, Naim AC, Greengard P. 1989. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J. Biol. Chem. 264:21748-59
20. Desdouits F, Cohen D, Naim AC, Greengard P, Girault JA. 1995. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase I in vitro and in vivo. J. Biol. Chem. 270:8772-78
21. Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E. 1994. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371:419-23
22. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, et al. 1999. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402:669-71
23. King MM, Huang CY, Chock PB, Nairn AC, Hemmings HC Jr, et al. 1984. Mammalian brain phosphoproteins as substrates for calcineurin. J. Biol. Chem. 259:8080-83
24. Nishi A, Snyder GL, Nairn AC, Greengard P. 1999. Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons. J. Neurochem. 72:2015-21
25. Desdouits F, Siciliano JC, Nairn AC, Greengard P, Girault JA. 1998. Dephosphorylation of Ser-137 in DARPP-32 by protein phosphatases 2A and 2C: different roles in vitro and in striatonigral neurons. Biochem. J. 330:211-16
26. Foster GA, Schultzberg M, Hökfelt T, Goldstein M, Hemmings HC Jr, et al. 1987. Development of a dopamine- and cyclic adenosine 3′:5′-monophosphate-regulated phosphoprotein (DARPP-32) in the prenatal rat central nervous system, and its relationship to the arrival of presumptive dopaminergic innervation. J. Neurosci. 7:1994-2018
27. Ehrlich ME, Rosen NL, Kurihara T, Shalaby IA, Greengard P. 1990. DARPP-32 development in the caudate nucleus is independent of afferent input from the substantia nigra. Brain Res. Dev. Brain Res. 54:257-63
28. Naimi S, Jeny R, Hantraye P, Peschanski M, Riche D. 1996. Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult rat brain. Exp. Neurol. 137:15-25
29. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, et al. 1998. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281:838-42
30. Ouimet CC, LaMantia AS, Goldman-Rakic P, Rakic P, Greengard P. 1992. Immunocytochemical localization of DARPP-32, a dopamine and cyclic-AMP-regulated phosphoprotein, in the primate brain. J. Comp. Neurol. 323:209-18
31. Kurihara T, Lewis RM, Eisler J, Greengard P. 1988. Cloning of cDNA for DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. J. Neurosci. 8:508-17
32. Ehrlich ME, Kurihara T, Greengard P. 1990. Rat DARPP-32: cloning, sequencing, and characterization of the cDNA. J. Mol. Neurosci. 2:1-10
33. Schalling M, Djurfeldt M, Hökfelt T, Ehrlich M, Kurihara T, Greengard P. 1990. Distribution and cellular localization of DARPP-32 mRNA in rat brain. Brain Res. Mol. Brain Res. 7:139-49
34. Kitai ST, Kocsis JD, Wood J. 1976. Origin and characteristics of the cortico-caudate afferents: an anatomical and electrophysiological study. Brain Res. 118:137-41
35. Donoghue JP, Herkenham M. 1986. Neostriatal projections from individual cortical fields conform to histochemically distinct striatal compartments in the rat. Brain Res. 365:397-403
36. Dahlström A, Fuxe K. 1964. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamine in the cell bodies of the brain stem neurons. Acta Physiol. Scand. 62:1-55
37. Steinbusch HW. 1981. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6:557-618
38. Yoshida M, Precht W. 1971. Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers. Brain Res. 32:225-28
39. Beckstead RM, Cruz CJ. 1985. Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience 19:147-58
40. Gerfen CR, Young WS III. 1988. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460:161-67
41. Kawaguchi Y, Wilson CJ, Emson PC. 1990. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10:3421-38
42. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. 1995. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18:527-35
43. Anderson KD, Reiner A. 1991. Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D1-like dopamine receptors on different types of striatal neurons. Brain Res. 568:235-43
44. Ouimet CC, Greengard P. 1990. Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J. Neurocytol. 19:39-52
45. Lloyd K, Hornykiewicz O. 1970. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science 170:1212-13
46. Kelly PH, Iversen SD. 1975. Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur. J. Pharmacol. 40:45-56
47. Hyman SE, Malenka RC. 2001. Addiction and the brain: the neurobiology of compulsion and its persistence. Nature Rev. Neurosci. 2:695-703
48. Stoof JC, Kebabian JW. 1981. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294:366-68
49. a. Sibley DR, Monsma FJ Jr. 1992. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:61-69
50. Lezcano N, Mrzljak, L, Eubanks S, Levenson R, Goldman-Rakic P, Bergson C. 1999. Dual signaling regulated by calcyon, a D1 receptor interacting protein. Science 287:1660-64
51. Nishi A, Snyder GL, Greengard P. 1997. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17:8147-55
52. Gerfen CR, Engber TM, Mallan LC, Susel Z, Chase TN, et al. 1990. D4 and D2 receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-32
53. +) ATPase activity in neostriatal neurons through D1 and D2 dopamine receptor synergism. Nature 347:386-88
54. Surmeier DJ, Son WJ, Yan Z. 1996. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16:6579-91
55. Aizman O, Brismar H, Uhlen P, Zettergren E, Levey AI, et al. 2000. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci. 3:226-30
56. Le Moine C, Bloch B. 1996. Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience 73:131-43
57. Robertson GS, Vincent SR, Fibiger HC 1990. Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos. Brain Res. 523:288-90
58. Chergui K, Svenningsson P, Nomikos GG, Gonon F, Fredholm BB, et al. 1997. Increased expression of NGFI-A mRNA in the rat striatum following burst stimulation of the medial forebrain bundle. Eur. J. Neurosci. 9:2370-82
59. Gonon F. 1997. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. J. Neurosci. 17:5972-78
60. West AR, Grace AA. 2002. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci. 22:294-304
61. 2A receptors. Proc. Natl. Acad. Sci. USA 97:1856-60
62. Lindskog M, Svenningsson P, Fredholm BB, Greengard P, Fisone G. 1999. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience 88:1005-8
63. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, et al. 2000. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA 97:12840-45
64. Fienberg AA, Greengard P. 2000. The DARPP-32 knockout mouse. Brain Res. Brain Res. Rev. 31:313-19
65. Snyder GL, Fienberg AA, Huganir RL, Greengard P. 1998. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18:10297-303
66. Flores-Hernandez J, Hernandez S, Snyder GL, Yan Z, Fienberg AA, et al. 2000. D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-32/PP1 signaling cascade. J. Neurophysiol. 83:2996-3004
67. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, et al. 2002. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J. Neurophysiol. 88:3010-20
68. Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, et al. 2000. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J. Neurosci. 20:8443-51
69. Liu FC, Graybiel AM. 1996. Spatiotemporal dynamics of CREB phosphorylation: transient versus sustained phosphorylation in the developing striatum. Neuron 17:1133-44
70. Svenningsson P, Fienberg AA, Allen PB, LeMoine C, Lindskog M, et al. 2000. Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32. J. Neurochem. 75:248-57
71. Parsons LH, Koob GF, Weiss F. 1995. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J. Pharmacol. Exp. Ther. 274:1182-91
72. Svenningsson P, Tzavara ET, Liu F, Fienberg AA, Nomikos GG, Greengard P. 2002. DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc. Natl. Acad. Sci. USA 99:3188-93
73. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, et al. 2001. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA 98:5300-5
74. Zachariou V, Benoit-Marand M, Allen PB, Ingrassia P, Fienberg AA, et al. 2002. Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1. Biol. Psychiatry 51:612-20
75. Halpain S, Girault J-A, Greengard P. 1990. Activation of NMDA receptors induced dephosphorylation of DARPP-32 in rat striatal slices. Nature 343:369-72
76. 2A. J. Naurochem. 81:832-41
77. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 252:851-53
78. MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL. 1986. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 321:519-22
79. Schoepp DD, Jane DE, Monn JA. 1999. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Nauropharmacology 38:1431-76
80. Tallaksen-Greene SJ, Kaatz KW, Romano C, Albin RL. 1998. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res. 780:210-17
81. Testa CM, Friberg IK, Weiss SW, Standaert DG. 1998. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J. Comp. Neurol. 390:5-19
82. Paolillo M, Montecucco A, Zanassi P, Schinelli S. 1998. Potentiation of dopamine-induced cAMP formation by group I metabotropic glutamate receptors via protein kinase C in cultured striatal neurons. Eur. J. Neurosci. 10:1937-45
83. Wang JQ, McGinty JF. 1998. Metabotropic glutamate receptor agonist increases neuropeptide mRNA expression in rat striatum. Brain Res. Mol. Brain Res. 54:262-69
84. Sacaan AI, Bymaster FP, Schoepp DD. 1992. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J. Neurochem. 59:245-51
85. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, et al. 2001. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 4:873-74
86. 2A receptor signaling. Proc. Natl. Acad. Sci. USA 100:1322-27
87. Heidinger V, Manzerra P, Wang XQ, Strasser U, Yu SP, et al. 2002. Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J. Neurosci. 22:5452-61
88. Peavy RD, Chang MS, Sanders-Bush E, Conn PJ. 2001. Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J. Neurosci. 21:9619-28
89. Gerfen CR, Miyachi S, Paletzki R, Brown P. 2002. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22:5042-54
90. Ferre S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, et al. 2002. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA 99:11940-45
91. Liu F, Virshup DM, Nairn AC, Greengard P. 2002. Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors. J. Biol. Chem. 277:43393-99
92. Liu F, Ma XH, Ule J, Bibb JA, Nishi A, et al. 2001. Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors. Proc. Natl. Acad. Sci. USA 98:11062-68
93. Snyder GL, Fisone G, Greengard P. 1994. Phosphorylation of DARPP-32 is regulated by GABA in rat striatum and substantia nigra. J. Neurochem. 63:1766-71
94. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57: 1062-67
95. 2A receptors. Prog. Neurobiol. 59:355-96
96. 2A and dopamine D1 receptors stimulates cAMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84:223-28
97. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, et al. 2002. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418:774-78
98. Snyder SH, Bredt DS. 1991. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 12:125-28
99. Tsou K, Snyder GL, Greengard P. 1993. Nitric oxide/cGMP pathway stimulates phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, in the substantia nigra. Proc. Natl. Acad. Sci. USA 90:3462-65
100. Shoffelmeer AN, Hansen HA, Stoof JC, Mulder AH. 1986. Blockade of D-2 dopamine receptors strongly enhances the potency of enkephalins to inhibit dopamine-sensitive adenylate cyclase in rat neostriatum: involvement of delta- and mu-opioid receptors. J. Neurosci. 6:2235-39
101. Georges F, Stinus L, Bloch B, Le Moine C. 1999. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur. J. Neurosci. 11:481-90
102. Lindskog M, Svenningsson P, Fredholm B, Greengard P, Fisone G. 1999. Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur. J. Neurosci. 11:2182-86
103. Vanderhaegen JJ, Signeau JC, Gepts W. 1975. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257:604-5
104. Dodd J, Kelly JS. 1981. The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. Brain Res. 205:337-50
105. Meyer DK, Beinfeld MC, Oertel WH, Brownstein MJ. 1982. Origin of the cholecystokinin-containing fibers in the rat caudatoputamen. Science 215:187-88
106. Snyder GL, Fisone G, Morino P, Gundersen V, Ottersen OP, et al. 1993. Regulation by the neuropeptide cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatum. Proc. Natl. Acad. Sci. USA 90:11277-81
107. Kitabgi P. 1989. Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways. Neurochem. Int. 14:111-19
108. Nemeroff CB. 1980. Neurotensin: perchance an endogenous neuroleptic? Biol. Psychiatry 15:283-302
109. Schotte A, Rostene W, Laduron PM. 1988. Different subcellular localization of neurotensin-receptor and neurotensin-acceptor sites in the rat brain dopaminergic system. J. Neurochem. 50:1026-31
110. Sarret P, Beaudet A, Vincent JP, Mazella J. 1998. Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain. J. Comp. Neurol. 394:344-56
111. Okuma Y, Fukuda Y, Osumi Y. 1983. Neurotensin potentiates the potassium-induced release of endogenous dopamine from rat striatal slices. Eur. J. Pharmacol. 93:27-33
112. Ferraro L, Tanganelli S, O'Connor WT, Bianchi C, Ungerstedt U, et al. 1995. Neurotensin increases endogenous glutamate release in the neostriatum of the awake rat. Synapse 20:362-64
113. 34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors. J. Neurochem. 81:325-34
114. Auger AP, Meredith JM, Snyder GL, Blaustein JD. 2001. Oestradiol increases phosphorylation of a dopamine- and cyclic AMP-regulated phosphoprotein (DARPP-32) in female rat brain. Eur. J. Neurosci. 13:761-68
115. Mani SK, Fienberg AA, O'Callaghan JP, Snyder GL, Allen PB, et al. 2000. Requirement for DARPP-32 in progesterone-facilitated sexual receptivity in female rats and mice. Science 287:1053-56
116. Meredith JM, Moffatt CA, Auger AP, Snyder GL, Greengard P, Blaustein JD. 1998. Mating-related stimulation induces phosphorylation of dopamine- and cyclic AMP-regulated phosphoprotein-32 in progestin receptor containing areas in the female rat brain. J. Neurosci. 18:10189-95
117. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, et al. 2003. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc. Natl. Acad. Sci. USA 100:4305-9
118. Pozzi L, Håkansson K, Usiello A, Borgkvist A, Lindskog M, et al. 2003. Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J. Neurochem. 86:451-60
119. i values. J. Pharmacol. Exp. Ther. 216:67-71
120. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. 2002. Neurobiology of depression. Neuron 34:13-25
121. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. 2002. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA 99:3182-87
122. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. 1989. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25:523-26
123. Picconi B, Centonze D, Håkansson K, Bernardi G, Greengard P, et al. 2003. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6:501-6
124. Maldve RE, Zhang TA, Ferrani-Kile K, Schreiber SS, Lippmann MJ, et al. 2002. DARPP-32 and regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens. Nat. Neurosci. 5:641-48
125. Risinger FO, Freeman PA, Greengard P, Fienberg AA. 2001. Motivational effects of ethanol in DARPP-32 knock-out mice. J. Neurosci. 21:340-48
126. Lovinger DM, White G, Weight FF. 1989. Ethanol inhibits NMDA-activated ion currents in hippocampal neurons. Science 243:1721-24
127. 2A receptor. Nature 388:674-78
128. Nestler EJ. 2001. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2:119-28
129. Bibb JA, Chen J, Taylor JR, Svenningsson P, Nishi A, et al. 2001. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 410:376-80
130. Deleted in proof
131. Hiroi N, Fienberg AA, Haile CN, Alburges M, Hanson GR, et al. 1999. Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur. J. Neurosci. 11:1114-18